Skip to content

Lung Cancer Health Center

Font Size

Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Malignant Mesothelioma Treatment

Prognosis in this disease is difficult to assess consistently because there is great variability in the time before diagnosis and the rate of disease progression. In large retrospective series of pleural mesothelioma patients, important prognostic factors were found to be:[1,2]

  • Stage.
  • Age.
  • Performance status.
  • Histology.

Various surgical procedures may be possible in selected patients, and they provide long-term survival without cure. For patients treated with aggressive surgical approaches, factors associated with improved long-term survival include the following:[3,4]

Recommended Related to Lung Cancer

Lung Cancer Resources

The National Comprehensive Cancer Network is a nonprofit alliance of 21 cancer centers throughout the U.S. that treat all cancers. National Comprehensive Cancer Network  

Read the Lung Cancer Resources article > >

  • Epithelial histology.
  • Negative lymph nodes.
  • Negative surgical margins.

For those patients treated with aggressive surgical approaches, nodal status is an important prognostic factor.[3] Median survival has been reported as 16 months for patients with malignant pleural disease and 5 months for patients with extensive disease. In some instances the tumor grows through the diaphragm making the site of origin difficult to assess. Cautious interpretation of treatment results with this disease is imperative because of the selection differences among series. Effusions, both pleural and peritoneal, represent major symptomatic problems for at least 66% of the patients. (Refer to the PDQ summary on Cardiopulmonary Syndromes for more information.) A history of asbestos exposure is reported in about 70% to 80% of all cases of mesothelioma.[1,5,6]

References:

  1. Ruffie P, Feld R, Minkin S, et al.: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7 (8): 1157-68, 1989.
  2. Tammilehto L, Maasilta P, Kostiainen S, et al.: Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration 59 (3): 129-35, 1992.
  3. Sugarbaker DJ, Strauss GM, Lynch TJ, et al.: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (6): 1172-8, 1993.
  4. de Perrot M, Feld R, Cho BC, et al.: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27 (9): 1413-8, 2009.
  5. Chailleux E, Dabouis G, Pioche D, et al.: Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 93 (1): 159-62, 1988.
  6. Adams VI, Unni KK, Muhm JR, et al.: Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer 58 (7): 1540-51, 1986.

    WebMD Public Information from the National Cancer Institute

    Last Updated: September 04, 2014
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1
    Next Article:

    Today on WebMD

    Broken cigarette
    Do you know the myths from the facts?
    man with a doctor
    Our health check will steer you in the right direction.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    15 Cancer Symptoms Men Ignore
    FEATURE
    Lung Cancer Risks Myths and Facts
    SLIDESHOW
     
    cancer fighting foods
    SLIDESHOW
    Improving Lung Cancer Survival Targeted Therapy
    VIDEO
     
    Lung Cancer Surprising Differences Between Sexes
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Lung Cancer Surgery Options
    VIDEO
     

    WebMD Special Sections